{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:21Z","timestamp":1740149001532,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Janssen Global Services LLC"},{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s12325-022-02270-7","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:02:44Z","timestamp":1660122164000},"page":"4613-4631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of Guselkumab on Work Productivity in Biologic-Na\u00efve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Jeffrey R.","family":"Curtis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasheen","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie J.","family":"Shiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2270_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957\u201370.","journal-title":"N Engl J Med"},{"key":"2270_CR2","doi-asserted-by":"crossref","unstructured":"Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology. 2012; 51:275\u201383.","DOI":"10.1093\/rheumatology\/ker216"},{"key":"2270_CR3","first-page":"680","volume":"35","author":"S Lee","year":"2010","unstructured":"Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. Pharm Ther. 2010;35:680\u20139.","journal-title":"Pharm Ther"},{"key":"2270_CR4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/rheumatology\/ker348","volume":"51","author":"L Bojke","year":"2012","unstructured":"Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. Rheumatology (Oxford). 2012;51:210\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"2270_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1586\/14737167.2015.965154","volume":"15","author":"P Kawalec","year":"2015","unstructured":"Kawalec P, Malinowski KP. The indirect costs of psoriatic arthritis: systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res. 2015;15:125\u201332.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2270_CR6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/ard.2010.149211","volume":"70","author":"A Davis","year":"2011","unstructured":"Davis A, Palaganas MP, Badley EM, et al. Measuring participation in people with spondyloarthritis using the social role participation questionnaire. Ann Rheum Dis. 2011;70:1765\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2270_CR7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1136\/annrheumdis-2016-210242","volume":"76","author":"A-M Orbai","year":"2017","unstructured":"Orbai A-M, de Wit M, Mease P, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76:673\u201380.","journal-title":"Ann Rheum Dis"},{"key":"2270_CR8","unstructured":"Tremfya (guselkumab). Package insert. Janssen Biotech, Inc; 2020."},{"key":"2270_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/1744666X.2020.1857733","volume":"17","author":"W-H Boehncke","year":"2021","unstructured":"Boehncke W-H, Brembilla NC, Nissen MJ. Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults. Expert Rev Clin Immunol. 2021;17:5\u201313.","journal-title":"Expert Rev Clin Immunol"},{"key":"2270_CR10","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-na\u00efve or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1115\u201325.","journal-title":"Lancet"},{"key":"2270_CR11","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-na\u00efve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet"},{"key":"2270_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke W-H, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7: e001457.","journal-title":"RMD Open"},{"key":"2270_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-na\u00efve patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604\u201316.","journal-title":"Arthritis Rheumatol"},{"key":"2270_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-na\u00efve patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385.","journal-title":"Arthritis Rheumatol"},{"key":"2270_CR15","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman DD, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665\u201373.","journal-title":"Arthritis Rheum"},{"key":"2270_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40744-019-0155-5","volume":"6","author":"W Tillett","year":"2019","unstructured":"Tillett W, Lin C-Y, Zbrozek A, TrevelinSprabery A, Birt J. A threshold of meaning for work disability improvement in psoriatic arthritis measured by the work productivity and activity impairment questionnaire. Rheumatol Ther. 2019;6:379\u201391.","journal-title":"Rheumatol Ther"},{"key":"2270_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"2270_CR18","unstructured":"Reilly Associates. WPAI:SHP v2.0 (updated August 18, 2010). http:\/\/www.reillyassociates.net\/WPAI_SHP.html. Accessed 26 May 2021."},{"key":"2270_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.23568","volume":"59","author":"PJ Healy","year":"2008","unstructured":"Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686\u201391.","journal-title":"Arthritis Rheum"},{"key":"2270_CR20","unstructured":"Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise\u2014the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol. 2007; 34:1740\u20135."},{"key":"2270_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3899\/jrheum.130163","volume":"40","author":"DD Gladman","year":"2013","unstructured":"Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357\u20139.","journal-title":"J Rheumatol"},{"key":"2270_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23\u201331.","journal-title":"J Dermatolog Treat"},{"key":"2270_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238\u201344.","journal-title":"Dermatologica"},{"key":"2270_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/JCI200318921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Investig. 2003;111:1805\u201312.","journal-title":"J Clin Investig"},{"key":"2270_CR25","first-page":"789","volume":"9","author":"JF Fries","year":"1982","unstructured":"Fries JF, Spitz P, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 1982;9:789\u201393.","journal-title":"J Rheumatol"},{"key":"2270_CR26","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1097\/00007632-200012150-00008","volume":"25","author":"JE Ware Jr","year":"2000","unstructured":"Ware JE Jr. SF-36 health survey update. Spine. 2000;25:3130\u20139.","journal-title":"Spine"},{"key":"2270_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group","year":"1990","unstructured":"The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"2270_CR28","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936\u20139.","journal-title":"Ann Rheum Dis"},{"key":"2270_CR29","unstructured":"OECD. Average wages (indicator). 2020. https:\/\/data.oecd.org\/earnwage\/average-wages.htm. Accessed 18 Nov 2021."},{"key":"2270_CR30","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1007\/s10067-021-05639-1","volume":"40","author":"A Ogdie","year":"2021","unstructured":"Ogdie A, Walsh JA, Chakravarty SD, et al. The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clin Rheumatol. 2021;40:3667\u201377.","journal-title":"Clin Rheumatol"},{"key":"2270_CR31","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3899\/jrheum.170874","volume":"45","author":"N Iragorri","year":"2018","unstructured":"Iragorri N, Hofmeister M, Spackman E, Hazlewood GS. The effect of biologic and targeted synthetic drugs on work- and productivity-related outcomes for patients with psoriatic arthritis: a systematic review. J Rheumatol. 2018;45:1124\u201330.","journal-title":"J Rheumatol"},{"key":"2270_CR32","first-page":"603","volume":"56","author":"W Tillett","year":"2017","unstructured":"Tillett W, Shaddick G, Jobling A, et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicenter observational cohort study of psoriatic arthritis. Rheumatology. 2017;56:603\u201312.","journal-title":"Rheumatology"},{"key":"2270_CR33","first-page":"1227","volume":"38","author":"W Tillett","year":"2020","unstructured":"Tillett W, Lin C-Y, TrevelinSprabery A, Birt JA, Kavanaugh A. Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials. Clin Exp Rheumatol. 2020;38:1227\u201330.","journal-title":"Clin Exp Rheumatol"},{"key":"2270_CR34","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s13075-018-1773-y","volume":"20","author":"LC Coates","year":"2018","unstructured":"Coates LC, Gladman DD, Nash P, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. Arthritis Res Ther. 2018;20:272.","journal-title":"Arthritis Res Ther"},{"key":"2270_CR35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/rheumatology\/key161","volume":"57","author":"AB Gottlieb","year":"2018","unstructured":"Gottlieb AB, Strand V, Kishimoto M, et al. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-na\u00efve patients with active psoriatic arthritis (SPIRIT-P1). Rheumatology (Oxford). 2018;57:1777\u201388.","journal-title":"Rheumatology (Oxford)"},{"key":"2270_CR36","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1468-3083.2011.04308.x","volume":"26","author":"R Gniadecki","year":"2012","unstructured":"Gniadecki R, Robertson D, Molta CT, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etancercept regimens. J Eur Acad Dermatol Venereol. 2012;26:1436\u201343.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2270_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s13075-021-02554-3","volume":"23","author":"P Rahman","year":"2021","unstructured":"Rahman P, Mease PJ, Helliwell PS, et al. Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response\u2014results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Res Ther. 2021;23:190.","journal-title":"Arthritis Res Ther"},{"key":"2270_CR38","unstructured":"Rahman P, Mease PJ, Deodhar A, et al. Relationships between fatigue and hemoglobin\/C-reactive protein levels and associations between fatigue and clinical response in patients with active psoriatic arthritis: results from two randomized controlled trials of guselkumab (Tremfya\u00ae) (Poster 1807). In: Presented at ACR convergence 2021; November 3\u20139, 2021."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02270-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02270-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:11:57Z","timestamp":1662948717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02270-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["2270"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02270-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}